/
BWAY
$15.17+$0.69 (+4.77%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$581.1M
40M shares
52-week range
$5.68 – $17.35
81% from low
Exchange
NASDAQ
ADRC
Price (6 mo)
Loading chart…
Change+$10.07
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.4M | $23.1M | $22.1M | $29.7M | $27.2M | $31.8M | $41.0M | $52.2M |
| Cost of revenue | $3.6M | $5.1M | $5.1M | $6.6M | $7.1M | $8.3M | $10.4M | $12.8M |
| Gross profit | $12.8M | $18.0M | $17.0M | $23.1M | $20.0M | $23.5M | $30.6M | $39.4M |
| Gross margin | 78.1% | 77.8% | 77.1% | 77.7% | 73.8% | 73.9% | 74.6% | 75.4% |
| R&D | $6.2M | $7.9M | $5.8M | $6.4M | $7.7M | $6.7M | $7.2M | $9.6M |
| Operating income | −$5.1M | −$8.5M | −$4.8M | −$5.0M | −$12.7M | −$5.0M | $1.4M | $4.3M |
| EBITDA | −$4.4M | −$6.7M | −$3.5M | −$4.7M | −$11.5M | −$2.6M | $5.4M | $11.5M |
| Net income | −$6.5M | −$10.3M | −$5.4M | −$6.5M | −$13.3M | −$4.2M | $2.9M | $7.6M |
| Net margin | -39.5% | -44.7% | -24.4% | -21.8% | -49.1% | -13.2% | 7.1% | 14.6% |
| EPS (diluted) | -0.39 | -0.50 | -0.24 | -0.21 | -0.43 | -0.13 | 0.09 | 0.36 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $68M | $0.33 | $0.26–$0.46 | 3 |
| 2027 | $85M | $0.54 | $0.37–$0.79 | 3 |
| 2028 | $109M | $0.57 | $0.54–$0.59 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Brainsway Ltd. American Depositary Shares
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
www.brainsway.com- Employees
- 129
- IPO / List date
- Apr 17, 2019
Held by traders on TradeandTell
No one on the platform currently holds BWAY.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 518,420 | $6.9M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-03-04 | 2-for-1 |
Recent trades on TradeandTell
No one on the platform has traded BWAY yet.
